OncoCyte (STU:7OC0) Other Net Income (Loss) : €-2.73 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is OncoCyte Other Net Income (Loss)?

OncoCyte's Other Net Income (Loss) for the three months ended in Dec. 2023 was €0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 was €-2.73 Mil.

OncoCyte's annual Other Net Income (Loss) declined from Dec. 2021 (€-18.13 Mil) to Dec. 2022 (€-51.25 Mil) but then increased from Dec. 2022 (€-51.25 Mil) to Dec. 2023 (€-2.68 Mil).

OncoCyte Other Net Income (Loss) Historical Data

The historical data trend for OncoCyte's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Other Net Income (Loss) Chart

OncoCyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

-18.13

-51.25

-2.68

OncoCyte Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Net Income (Loss)	Get a 7-Day Free Trial															-31.12	-2.73	-	-	-

OncoCyte Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.73 Mil.

OncoCyte Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of OncoCyte's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoCyte (STU:7OC0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OncoCyte Corp (STU:7OC0) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

OCX:USA

Address

15 Cushing, Irvine, CA, USA, 92618

Website

https://www.oncocyte.com

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.

OncoCyte (STU:7OC0) Headlines

No Headlines